Boston Scientific is picking up a single-use device for the removal of uterine polyps in its acquisition of Distal Access’ gynecology and urology portfolio. The financial details of the deal were not disclosed.
The Resectr is a disposable, nonpowered, hand-held device that is compatible with various hysteroscopes. It is used for the treatment of uterine polyps in a doctor’s office, hospital or ambulatory surgery center. Uterine polyps, which can cause abnormal bleeding and infertility, affect as many as 80% of women. More than 400,000 polypectomies are done each year in the U.S., according to a statement.
“The Resectr device is exactly the type of innovation we need to help make healthcare more cost-effective and accessible for physicians and their patients," said David Pierce, senior vice president and president of Boston Scientific’s urology and pelvic health business, in the statement. "This acquisition is part of our commitment to advance comprehensive solutions for women's health that can help physicians provide high-quality care."
The new acquisition will be folded into Boston Sci’s urology and pelvic health unit, which includes devices for the removal of uterine tissue and for the treatment of abnormal uterine bleeding, as well as pelvic floor reconstruction devices and urethral slings.
Boston Scientific has been on an acquisition spree of late, picking up Cosman Medical in July to boost its neuromodulation unit, stacking its endoscopy division with its $210 million acquisition of EndoChoice in September and snagging an in-development endoscopic tissue retractor from LumenR last month.